Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants

European Child and Adolescent Psychiatry

Volumn 19, Issue 4, 2010, Pages 325-340

  Buitelaar, Jan ^a,b   Medori, Rossella ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c NONE   (Germany)

Author keywords

ADHD; Children; Methylphenidate; OROS MPH; Quality of life

Indexed keywords

ATOMOXETINE; LONG ACTING DRUG; METHYLPHENIDATE; OROS; PLACEBO; UNCLASSIFIED DRUG;

ADDICTION; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; CHILD DEVELOPMENT; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EXTENDED DRUG RELEASE; GROWTH DISORDER; HUMAN; HYPERACTIVITY; IMMEDIATE DRUG RELEASE; INSOMNIA; IRRITABILITY; LONG TERM CARE; MENTAL DISEASE; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL ADAPTATION; SOCIAL COMPETENCE; SOMNOLENCE; STOMACH PAIN; SUICIDE; TIC; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; HUMANS; METHYLPHENIDATE; PERSONALITY DEVELOPMENT; PROPYLAMINES; QUALITY OF LIFE; SOCIAL PERCEPTION; TREATMENT OUTCOME;

EID: 77950865353     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-009-0056-1     Document Type: Review

References (121)

1. H Abikoff J McGough B Vitiello J McCracken M Davies J Walkup M Riddle M Oatis L Greenhill A Skrobala J March P Gammon J Robinson R Lazell DJ McMahon L Ritz 2005 Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders J Am Acad Child Adolesc Psychiatry 44 418 427 15843763
2. American Psychiatric Association (1994) Diagnsotic and statistical manual for mental disorders: fourth edition (DSM-IV). American Psychiatric Association, Washington, DC
3. CL Bagwell BS Molina WE Pelham Jr B Hoza 2001 Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence J Am Acad Child Adolesc Psychiatry 40 1285 1292 1:STN:280:DC%2BD3MnkslCntA%3D%3D 11699802
4. T Banaschewski D Coghill P Santosh A Zuddas P Asherson J Buitelaar M Danckaerts M Dopfner SV Faraone A Rothenberger J Sergeant HC Steinhausen EJ Sonuga-Barke E Taylor 2006 Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 15 476 495 16680409 (Pubitemid 46020533)
5. RA Barkley 2004 Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments J Psychiatr Pract 10 39 56 15334986
6. Barkley RA (1998) Attention-deficit hyperactivity disorder. A handbook for diagnosis and treatment, 2nd edn. The Guildford Press, New York
7. RA Barkley 2002 Psychosocial treatments for attention-deficit/ hyperactivity disorder in children J Clin Psychiatry 63 Suppl 12 36 43 12562060 (Pubitemid 36025586)
8. A Bener RA Qahtani I Abdelaal 2006 The prevalence of ADHD among primary school children in an Arabian society J Atten Disord 10 77 82 16840595 (Pubitemid 44060287)
9. J Biederman 1998 Attention-deficit/hyperactivity disorder: a life-span perspective J Clin Psychiatry 59 4 16 9680048 (Pubitemid 28317217)
10. J Biederman 2003 Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD J Clin Psychiatry 64 3 8 1:CAS:528:DC%2BD3sXotl2ru70%3D 14529323 (Pubitemid 37169642)
11. J Biederman MC Monuteaux T Spencer TE Wilens HA Macpherson SV Faraone 2008 Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study Am J Psychiatry 165 597 603 18316421 (Pubitemid 351705336)
12. J Biederman J Newcorn S Sprich 1991 Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders Am J Psychiatry 148 564 577 1:STN:280:DyaK3M3gs1KjsA%3D%3D 2018156
13. Bloom B, Dey AN, Freeman G (2006) Summary health statistics for US children: national health interview survey, 2005. Vital Health Stat 231:1-84
14. JK Buitelaar TE Wilens S Zhang Y Ning PD Feldman 2009 Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo J Child Psychol Psychiatry 50 335 342 19309330
15. E Chan C Zhan CJ Homer 2002 Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey Arch Pediatr Adolesc Med 156 504 511 11980558 (Pubitemid 34492585)
16. Characteristics SSoP http://www.keele.ac.uk/schools/pharm/MTRAC/ ProductInfo/verdicts/A/ATOMOXETINE.PDF
17. WJ Chou MC Chou RF Tzang YC Hsu SS Gau SJ Chen YY Wu YF Huang HY Liang H Cheng 2009 Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes Psychiatry Clin Neurosci 63 167 175 1:CAS:528:DC%2BD1MXlsFOnsrk%3D 19335386
18. AM Chronis HA Jones VL Raggi 2006 Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder Clin Psychol Rev 26 486 502 16483703
19. D Coghill C Soutullo C d'Aubuisson U Preuss T Lindback M Silverberg J Buitelaar 2008 Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey Child Adolesc Psychiatry Ment Health 2 31 18957105
20. DJ Cox JW Humphrey RL Merkel JK Penberthy B Kovatchev 2004 Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder J Am Board Fam Pract 17 235 239 15243010
21. DJ Cox RL Merkel M Moore F Thorndike C Muller B Kovatchev 2006 Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder Pediatrics 118 e704 e710 16950962 (Pubitemid 46089997)
22. DJ Cox RL Merkel JK Penberthy B Kovatchev CS Hankin 2004 Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study J Am Acad Child Adolesc Psychiatry 43 269 275 15076259 (Pubitemid 41615005)
23. IR Diamond R Tannock RJ Schachar 1999 Response to methylphenidate in children with ADHD and comorbid anxiety J Am Acad Child Adolesc Psychiatry 38 402 409 1:STN:280:DyaK1M3hsFehtg%3D%3D 10199111 (Pubitemid 29153111)
24. G Donenberg BL Baker 1993 The impact of young children with externalizing behaviors on their families J Abnorm Child Psychol 21 179 198 1:STN:280:DyaK3s3mtVWqtg%3D%3D 8491931 (Pubitemid 23141442)
25. Excellence NIfC (2006) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. National Institute for Clinical Excellence, October 2003. http://www.nice.org.uk
26. Faber A, van Agthoven M, Kalverdijk L (2006) Cost effectiveness of long-acting methylphenidate OROS (Concerta XL) in ADHD youths with suboptimal symptom control of immediate-release methylphenidate in The Netherlands. Poster presented at ISPOR 9th annual European congress, Copenhagen, Denmark, 28-31 Oct 2006
27. SV Faraone J Biederman CP Morley TJ Spencer 2008 Effect of stimulants on height and weight: a review of the literature J Am Acad Child Adolesc Psychiatry 47 994 1009 18580502
28. SV Faraone J Sergeant C Gillberg J Biederman 2003 The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2 104 113 16946911
29. A Favreau G Deseille-Turlotte F Brault B Giraudeau C Krier MA Barthez P Castelnau 2006 Benefit of the extended-release methylphenidate formulations: a comparative study in childhood Arch Pediatr 13 442 448 1:STN:280: DC%2BD28zjvFegsA%3D%3D 16597499
30. Fischer AG, Bau CH, Grevet EH, Salgado CA, Victor MM, Kalil KL, Sousa NO, Garcia CR, Belmonte-de-Abreu P (2007) The role of comorbid major depressive disorder in the clinical presentation of adult ADHD. J Psychiatr Res 41(12):991-996 (Pubitemid 47301943)
31. EJ Garland 1998 Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats J Psychopharmacol 12 385 395 1:CAS:528:DyaK1MXpsVSmtA%3D%3D 10065914 (Pubitemid 28561444)
32. SS Gau HY Shen MC Chou CS Tang YN Chiu CS Gau 2006 Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures J Child Adolesc Psychopharmacol 16 286 297 16768636
33. LL Greenhill JM Halperin H Abikoff 1999 Stimulant medications J Am Acad Child Adolesc Psychiatry 38 503 512 1:STN:280:DyaK1M3ks1OqtA%3D%3D 10230181 (Pubitemid 29203465)
34. K Gucuyener AK Erdemoglu S Senol A Serdaroglu S Soysal AI Kockar 2003 Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities J Child Neurol 18 109 112 12693777 (Pubitemid 36432338)
35. J Guevara P Lozano T Wickizer L Mell H Gephart 2001 Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder Pediatrics 108 71 78 1:STN:280:DC%2BD3MznslWitQ%3D%3D 11433056 (Pubitemid 32592007)
36. Hartup WW (1992) Having friends, making friends and keeping friends: relationships as educational contexts. Urban, IL: ERIC Clearing house on elementary and early childhood education. Eric Digest 345 854
37. L Hechtman 2000 Assessment and diagnosis of attention-deficit/ hyperactivity disorder Child Adolesc Psychiatr Clin N Am 9 481 498 1:STN:280:DC%2BD3M%2FmslWqsA%3D%3D 10944652 (Pubitemid 30620539)
38. L Hechtman H Abikoff RG Klein G Weiss C Respitz J Kouri C Blum B Greenfield J Etcovitch K Fleiss S Pollack 2004 Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment J Am Acad Child Adolesc Psychiatry 43 812 819 15213582 (Pubitemid 38808486)
39. S Heger GE Trott M Meusers E Schulz A Rothenberger K Rettig R Medori A Schreiner H Remschmidt 2006 Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD Zeitschrift fur Kinder and Jugendpsychiatrie Psychotherapie 34 257 265
40. SA Hemmer JF Pasternak SG Zecker BL Trommer 2001 Stimulant therapy and seizure risk in children with ADHD Pediatr Neurol 24 99 102 1:STN:280: DC%2BD3M7os1OhsQ%3D%3D 11275457
41. P Hoare T Beattie 2003 Children with attention deficit hyperactivity disorder and attendance at hospital Eur J Emerg Med 10 98 100 12789063
42. P Hoare H Remschmidt R Medori C Ettrich A Rothenberger P Santosh M Schmit Q Spender R Tamhne M Thompson C Tinline GE Trott 2005 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/ hyperactivity disorder switched from MPH Eur Child Adolesc Psychiatry 14 305 309 16220214
43. A James FH Lai C Dahl 2004 Attention deficit hyperactivity disorder and suicide: a review of possible associations Acta Psychiatr Scand 110 408 415 1:STN:280:DC%2BD2crkvF2ktg%3D%3D 15521824
44. PS Jensen SP Hinshaw HC Kraemer N Lenora JH Newcorn HB Abikoff JS March LE Arnold DP Cantwell CK Conners GR Elliott LL Greenhill L Hechtman B Hoza WE Pelham JB Severe JM Swanson KC Wells T Wigal B Vitiello 2001 ADHD comorbidity findings from the MTA study: comparing comorbid subgroups J Am Acad Child Adolesc Psychiatry 40 147 158 1:STN:280:DC%2BD3M7ktFCnsA%3D%3D 11211363
45. C Johnson EJ Mash 2001 Families with children with ADHD: review and recommendations for future research Clin Child Fam Psychol Rev 3 183 207
46. TM Kelly JR Cornelius DB Clark 2004 Psychiatric disorders and attempted suicide among adolescents with substance use disorders Drug Alcohol Depend 73 87 97 14687963
47. JE Kemner MJ Lage 2006 Effect of methylphenidate formulation on treatment patterns and use of emergency room services Am J Health Syst Pharm 63 317 322 16452517
48. JE Kemner HL Starr PE Ciccone CG Hooper-Wood RS Crockett 2005 Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study Adv Ther 22 498 512 1:CAS:528:DC%2BD28XhtlWksr8%3D 16418159 (Pubitemid 43130867)
49. Y Kim MS Shin JW Kim HJ Yoo SC Cho BN Kim 2009 Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD Hum Psychopharmacol 24 95 102 1:CAS:528:DC%2BD1MXktFGnur0%3D 19226534
50. AF Klassen A Miller S Fine 2004 Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder Pediatrics 114 e541 e547 15520087 (Pubitemid 41655750)
51. SH Kollins 2003 Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient J Clin Psychiatry 64 14 18 1:CAS:528:DC%2BD3sXotl2ru7s%3D 14529325
52. CJ Kratochvil JH Heiligenstein R Dittmann TJ Spencer J Biederman J Wernicke JH Newcorn C Casat D Milton D Michelson 2002 Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial J Am Acad Child Adolesc Psychiatry 41 776 784 12108801 (Pubitemid 38338092)
53. S Kutcher M Aman SJ Brooks J Buitelaar E van Daalen J Fegert RL Findling S Fisman LL Greenhill M Huss V Kusumakar D Pine E Taylor S Tyano 2004 International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions Eur Neuropsychopharmacol 14 11 28 1:CAS:528:DC%2BD3sXps1Gkur0%3D 14659983 (Pubitemid 37495027)
54. M Lage P Hwang 2004 Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment J Child Adolesc Psychopharmacol 14 575 581 15662149
55. Landgraft JL, Abetz K, Ware JE (1996) The CHQ user's manual. The Health Institute, New England Medical Center, Boston
56. GB LeFever KV Dawson AL Morrow 1999 The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools Am J Public Health 89 1359 1364 1:STN:280:DyaK1Mvgtlyjsw%3D%3D 10474553
57. CL Leibson SK Katusic WJ Barbaresi J Ransom PC O'Brien 2001 Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder JAMA 285 60 66 1:STN:280: DC%2BD3M%2FpsVSkug%3D%3D 11150110 (Pubitemid 32042717)
58. F Lynch C Mills I Daly C Fitzpatrick 2006 Challenging times: prevalence of psychiatric disorders and suicidal behaviours in Irish adolescents J Adolesc 29 555 573 16202448 (Pubitemid 44070564)
59. S Mannuzza RG Klein A Bessler P Malloy M LaPadula 1993 Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status Arch Gen Psychiatry 50 565 576 1:STN:280:DyaK3szgsV2qtg%3D%3D 8317950 (Pubitemid 23203567)
60. S Mannuzza RG Klein NL Truong JL Moulton 3rd ER Roizen KH Howell FX Castellanos 2008 Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood Am J Psychiatry 165 604 609 18381904 (Pubitemid 351705337)
61. A Marchetti R Magar H Lau EL Murphy PS Jensen CK Conners R Findling E Wineburg I Carotenuto TR Einarson M Iskedjian 2001 Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis Clin Ther 23 1904 1921 1:STN:280:DC%2BD38%2Fkt1emuw%3D%3D 11768842 (Pubitemid 33121978)
62. A McClure S Prasad L Poole 2005 Functional outcomes of children with attention deficit hyperactivity disorder in the UK Arch Dis Childhood 90 A48 A50
63. BS Molina K Flory SP Hinshaw AR Greiner LE Arnold JM Swanson L Hechtman PS Jensen B Vitiello B Hoza WE Pelham GR Elliott KC Wells HB Abikoff RD Gibbons S Marcus CK Conners JN Epstein LL Greenhill JS March JH Newcorn JB Severe T Wigal 2007 Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects J Am Acad Child Adolesc Psychiatry 46 1028 1040 17667481 (Pubitemid 47220685)
64. BS Molina SP Hinshaw JM Swanson LE Arnold B Vitiello PS Jensen JN Epstein B Hoza L Hechtman HB Abikoff GR Elliott LL Greenhill JH Newcorn KC Wells T Wigal RD Gibbons K Hur PR Houck 2009 The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study J Am Acad Child Adolesc Psychiatry 48 484 500 19318991
65. JL Moore JW McAuley L Long R Bornstein 2002 An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients Epilepsy Behav 3 92 95 12609358 (Pubitemid 35174434)
66. K Murphy 2005 Psychosocial treatments for ADHD in teens and adults: a practice-friendly review J Clin Psychol 61 607 619 15723366 (Pubitemid 40776547)
67. K Murphy RA Barkley 1996 Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments Compr Psychiatry 37 393 401 1:STN:280:DyaK2s%2Fos12gtg%3D%3D 8932963 (Pubitemid 26383062)
68. S Nada-Raja JD Langley R McGee SM Williams DJ Begg AI Reeder 1997 Inattentive and hyperactive behaviors and driving offenses in adolescence J Am Acad Child Adolesc Psychiatry 36 515 522 1:STN:280:DyaK2s3lsFSlsw%3D%3D 9100426 (Pubitemid 27149189)
69. National Institute for Clinical Excellence (2000) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. October
70. National Institute for Clinical Excellence (2006) Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults 2006. http://www.nice.org.uk/guidance/index.jsp?action= download&o=34227
71. National Institute for Clinical Excellence (2003) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood
72. JH Newcorn CJ Kratochvil AJ Allen CD Casat DD Ruff RJ Moore D Michelson 2008 Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response Am J Psychiatry 165 721 730 18281409 (Pubitemid 351810541)
73. SE Nissen 2006 ADHD drugs and cardiovascular risk N Engl J Med 354 1445 1448 1:CAS:528:DC%2BD28XjtFWhsLY%3D 16549404
74. GA O'Driscoll L Depatie AL Holahan T Savion-Lemieux RG Barr C Jolicoeur VI Douglas 2005 Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder Biol Psychiatry 57 1452 1460 15950020 (Pubitemid 40798567)
75. JA Owens R Maxim C Nobile M McGuinn M Msall 2000 Parental and self-report of sleep in children with attention-deficit/hyperactivity disorder Arch Pediatr Adolesc Med 154 549 555 1:STN:280:DC%2BD3czgs1KksQ%3D%3D 10850500 (Pubitemid 30387374)
76. D Palumbo T Spencer J Lynch H Co-Chien SV Faraone 2004 Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy J Child Adolesc Psychopharmacol 14 185 194 15319016 (Pubitemid 38988785)
77. WE Pelham EM Gnagy L Burrows-Maclean A Williams GA Fabiano SM Morrisey AM Chronis GL Forehand CA Nguyen MT Hoffman TM Lock K Fielbelkorn EK Coles CJ Panahon RL Steiner DL Meichenbaum AN Onyango GD Morse 2001 Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings Pediatrics 107 E105 1:STN:280:DC%2BD3Mzhs1Onsg%3D%3D 11389303
78. JM Perrin RA Friedman TK Knilans 2008 Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder Pediatrics 122 451 453 18676566
79. S Pliszka American Academy of Child and Adolescent Psychiatry 2007 Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 894 921 17581453
80. SR Pliszka 1989 Effect of anxiety on cognition, behavior, and stimulant response in ADHD J Am Acad Child Adolesc Psychiatry 28 882 887 1:STN:280:DyaK3c%2Fjs1Kjuw%3D%3D 2808258
81. G Polanczyk MS de Lima BL Horta J Biederman LA Rohde 2007 The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry 164 942 948 17541055
82. A Poulton CT Cowell 2003 Slowing of growth in height and weight on stimulants: a characteristic pattern J Paediatr Child Health 39 180 185 1:STN:280:DC%2BD3s7pvVWjtA%3D%3D 12654140
83. MD Rapport C Moffitt 2002 Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects Clin Psychol Rev 22 1107 1131 12436807
84. H Remschmidt P Hoare C Ettrich A Rothenberger P Santosh M Schmidt Q Spender R Tamhne M Thompson C Tinline GE Trott R Medori 2005 Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study Eur Child Adolesc Psychiatry 14 297 304 1:STN:280:DC%2BD2Mrktlemtg%3D%3D 16220213
85. Robb A, Stein M (2002) Parent preference for OROS methylphenidate over methylphenidate tid. Poster presented at 155th annual meeting of the American Psychiatry Association, Philadelphia, 18-23 May 2002
86. Scottish Intercollegiate Guidelines Network (2001) Attention deficit and hyperkinetic disorders in children and young people. A national clinical guidelines No. 52. SIGN, Edinburgh
87. EK Sleator RK Ulmann A von Neumann 1982 How to hyperactive children feel about taking stimulatnts and will they tell their doctor? Clin Pediatr 21 474 479 1:STN:280:DyaL383gvFCmtw%3D%3D
88. E Sobanski B Alm 2005 Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder Nervenarzt 76 1412 1417 1:STN:280:DC%2BD2MnkvFOjtw%3D%3D 15756530
89. E Sobanski B Alm B Krumm 2007 Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder Nervenarzt 78 328 337 1:STN:280:DC%2BD2s7ktVensA%3D%3D 16544121
90. T Spencer J Biederman T Wilens M Harding D O'Donnell S Griffin 1996 Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle J Am Acad Child Adolesc Psychiatry 35 409 432 1:STN:280: DyaK2s%2FnslWgtQ%3D%3D 8919704
91. TJ Spencer SV Faraone J Biederman M Lerner KM Cooper B Zimmerman 2006 Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 45 527 537 16670649
92. Starfield B, Riley A, Ensminger M (2000) Manual for the child health and illness profile-child edition (CHIP-CE). The John Hopkins University, Baltimore, MD
93. HL Starr J Kemner 2005 Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD J Natl Med Assoc 97 11S 16S 16350601
94. M Steele M Weiss J Swanson J Wang RS Prinzo CE Binder 2006 A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder Can J Clin Pharmacol 13 e50 e62 16456216
95. MA Stein 1999 Unravelling sleep problems in treated and untreated children with ADHD J Child Adolesc Psychopharmacol 9 157 168 1:STN:280:DyaK1MvkvFeiuw%3D%3D 10521009
96. MA Stein CS Sarampote ID Waldman AS Robb C Conlon PL Pearl DO Black KE Seymour JH Newcorn 2003 A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder Pediatrics 112 e404 14595084
97. J Swanson 2003 Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement CNS Drugs 17 117 131 12521359
98. J Swanson S Gupta D Guinta D Flynn D Agler M Lerner L Williams I Shoulson S Wigal 1999 Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children Clin Pharmacol Ther 66 295 305 1:CAS:528:DyaK1MXmsFOjtLY%3D 10511066 (Pubitemid 29451762)
99. J Swanson S Gupta A Lam I Shoulson M Lerner N Modi E Lindemulder S Wigal 2003 Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies Arch Gen Psychiatry 60 204 211 1:CAS:528: DC%2BD3sXhsFyntbo%3D 12578439
100. Swanson J, Sadeh A, Lerner M (2001) Comparison of the impact of OROS methylphenidate HCL with methylphenidate tid and placebo on the sleep of children with ADHD. Reported in: Keating GM, McClellan K, Jarvis B. Methylphendiate (OROS formulation). CNS Drugs 15:495-503
101. JM Swanson GR Elliott LL Greenhill T Wigal LE Arnold B Vitiello L Hechtman JN Epstein WE Pelham HB Abikoff JH Newcorn BS Molina SP Hinshaw KC Wells B Hoza PS Jensen RD Gibbons K Hur A Stehli M Davies JS March CK Conners M Caron ND Volkow 2007 Effects of stimulant medication on growth rates across 3 years in the MTA follow-up J Am Acad Child Adolesc Psychiatry 46 1015 1027 17667480
102. R Tannock A Ickowicz R Schachar 1995 Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety J Am Acad Child Adolesc Psychiatry 34 886 896 1:STN:280: DyaK2MznvVWruw%3D%3D 7649959
103. E Taylor M Dopfner J Sergeant P Asherson T Banaschewski J Buitelaar D Coghill M Danckaerts A Rothenberger E Sonuga-Barke HC Steinhausen A Zuddas 2004 European clinical guidelines for hyperkinetic disorder-first upgrade Eur Child Adolesc Psychiatry 13 Suppl 1 17 30 (Pubitemid 39172160)
104. The MTA Cooperative Group 1999 A 14-month randomised clinical trial of treatment of strategies for attention deficit hyperactivity disorder Arch Gen Psychiatry 56 1073 1086
105. AR Torres J Whitney J Gonzalez-Heydrich 2008 Attention-deficit/ hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment Epilepsy Behav 12 217 233 18065271
106. Trautmann-Villalba P, Gerhold M, Polowczyk M, Dinter-Jorg M, Laucht M, Esser G, Schmidt MH (2001) Mother-child interaction and externalizing disorders in elementary schoolchildren. Zeitschrift fur Kinder und Jugendpsychiatri Psychotherapie 29(4):263-273
107. CM van der Feltz-Cornelis AP Aldenkamp 2006 Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial Epilepsy Behav 8 659 662 16504592
108. KB van der Heijden MG Smits WB Gunning 2006 Sleep hygiene and actigraphically evaluated sleep characteristics in children with ADHD and chronic sleep onset insomnia J Sleep Res 15 55 62 16490003
109. AL Vance ES Luk J Costin BJ Tonge C Pantelis 1999 Attention deficit hyperactivity disorder: anxiety phenomena in children treated with psychostimulant medication for 6 months or more Aust N Z J Psychiatry 33 399 406 1:STN:280:DyaK1MzmvFCjtA%3D%3D 10442797
110. Vanoverbeke N, Annemans L, Ingham M, Price M, Adriaenssen I (2003) A cost-consequence analysis of the management of attention deficit hyperactivity disorder (ADHD) in the UK. Poster presented at ISPOR 8th annual meeting, Arlington, VA, 18-21 May 2003
111. ND Volkow JM Swanson 2008 Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 165 553 555 18450933
112. Y Wang Y Zheng Y Du DH Song YJ Shin SC Cho BN Kim DH Ahn ME Marquez-Caraveo H Gao DW Williams LR Levine 2007 Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial Aust N Z J Psychiatry 41 222 230 1:CAS:528:DC%2BD1cXmsFWks7Y%3D 17464703
113. KC Wells TC Chi SP Hinshaw JN Epstein L Pfiffner M Nebel-Schwalm EB Owens LE Arnold HB Abikoff CK Conners GR Elliot LL Greenhill L Hechtman B Hoza PS Jensen J March JH Newcorn WE Pelham JB Severe J Swanson B Vitiello T Wigal 2006 Treatment-related changes in objectively measured parenting behaviours in the multimodal treatment study of children with attention-deficit/hyperactivity disorder J Consult Clin Psychol 74 649 657 16881772
114. T Wilens K McBurnett M Stein M Lerner T Spencer M Wolraich 2005 ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study J Am Acad Child Adolesc Psychiatry 44 1015 1023 16175106
115. T Wilens W Pelham M Stein CK Conners H Abikoff M Atkins G August L Greenhill K McBurnett D Palumbo J Swanson M Wolraich 2003 ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study J Am Acad Child Adolesc Psychiatry 42 424 433 12649629
116. TE Wilens SV Faraone J Biederman S Gunawardene 2003 Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics 111 179 185 12509574 (Pubitemid 36071051)
117. TE Wilens PG Hammerness J Biederman A Kwon TJ Spencer S Clark M Scott A Podolski JW Ditterline MC Morris H Moore 2005 Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder J Clin Psychiatry 66 253 259 15705013
118. TE Wilens K McBurnett O Bukstein J McGough L Greenhill M Lerner MA Stein CK Conners J Duby J Newcorn CE Bailey CJ Kratochvil D Coury C Casat MJ Denisco P Halstead L Bloom BA Zimmerman J Gu KM Cooper JM Lynch 2006 Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder Arch Pediatr Adolesc Med 160 82 90 16389216
119. TE Wilens TJ Spencer 2000 The stimulants revisited Child Adolesc Psychiatr Clin N Am 9 573 603 1:STN:280:DC%2BD3M%2FmslWqug%3D%3D 10944658
120. ML Wolraich MA Doffing 2004 Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate CNS Drugs 18 243 250 1:CAS:528:DC%2BD2cXjtl2gsrg%3D 15015904
121. ML Wolraich LL Greenhill W Pelham J Swanson T Wilens D Palumbo M Atkins K McBurnett O Bukstein G August 2001 Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder Pediatrics 108 883 892 1:STN:280:DC%2BD3MrjsVKjsw%3D%3D 11581440